For patients with advanced cancer, early-phase trials may represent the last best hope of significant anticancer response. For clinicians, every early phase trial holds virtually unlimited promise and hope of becoming the next immunotherapy or hot antibody-drug conjugate. However, early-phase trials also come with significant uncertainty of efficacy, toxicity and even dosing.

A recent Limbic article (link below) reported on an article published in ESMO Open that investigated the burden of "time toxicity" for patients enrolled in early-phase clinical trials, and advocated for this to be minimised. While it is essential to consider logistic factors and patient preferences, early-phase trials are frequently more inflexible compared to phase II or III studies, and are constructed as such to ensure patient safety in the face of significant unknowns.

In this episode of Fireside Chats, Michael and Josh discuss the pros and cons of attempting to streamline early phase trials, if it is possible, and what can be done to minimise a trial's impact on a patient's day-to-day and quality of life.

Article discussed in this episode (subscription may be required):

"‘Time toxicity’ burden for patients in early phase cancer trials," by Siobhan Calafiore

Available from: https://thelimbic.com/oncology/time-toxicity-burden-for-patients-in-early-phase-cancer-trials/?utm_source=sfmc&utm_medium=email&utm_campaign=Onc%201.12.23&utm_term=Read%20more&utm_id=91262&uid=12231&lk=0d144a028ccc3d800f567af6e9fa7662

Art courtesy of Taryn Silver

Audio courtesy of:

• Olexy on pixabay: https://pixabay.com/users/olexy-25300778/
• JuliusH on pixabay: https://pixabay.com/users/juliush-3921568/

The opinions discussed in this episode are those of the authors and should not be taken for medical advice. They exist to engender discussion, debate and thought.

Hosted on Acast. See acast.com/privacy for more information.